Sinovac to market LG Life Sciences vaccines in China
Sinovac Biotech, one of the leading emerging biotechnology companies in China, is to act as exclusive distributor in the Peoples Republic of China (PRC) for the hepatitis B vaccine produced by South Korean pharmaceutical company LG Life Sciences (LGLS).
Sinovac Biotech, one of the leading emerging biotechnology companies in China, is to act as exclusive distributor in the Peoples Republic of China (PRC) for the hepatitis B vaccine produced by South Korean pharmaceutical company LG Life Sciences (LGLS).
LGLS is exporting its Hepatitis B vaccine, EUVAX BTM, to more than 60 countries including those on UN-sponsored programmes. Sinovac believes the second-generation vaccine for hepatitis B, developed in 1991, will compare favorably to vaccines in the PRC.
"This agreement fits very well with our overall business strategy, once we successfully register EUVAX, we will have another sales revenue generator for Sinovac," said In-Chull Kim, president and ceo of LGLS.
Health experts estimate some 60% of China's 1.3bn people have been infected with Hepatitis B at some time in their lives, and 10% are infected now.